Download Files:
LKY-047
$750 – $2,250
Products Details
Product Description
– LKY-047, a Decursin derivative, is a potent and selective reversible competitive cytochrome P45022J2 (CYP2J2) inhibitor with an IC50 of 1.7 μM. LKY-047 is inactive against other human P450s, such as CYPs 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A[1].
Web ID
– HY-117026
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Metabolism-sugar/lipid metabolism
Molecular Formula
– C23H19NO7
References
– [1]Nguyen Minh Phuc, et al. LKY-047: First Selective Inhibitor of Cytochrome P450 2J2. Drug Metab Dispos. 2017 Jul;45(7):765-769.
CAS Number
– 1954681-29-8
Molecular Weight
– 421.40
Compound Purity
– 98.85
SMILES
– O=C(O[C@H]1CC(C=C(C=CC(O2)=O)C2=C3)=C3OC1(C)C)/C=C/C4=CC=C([N+]([O-])=O)C=C4
Clinical Information
– No Development Reported
Research Area
– Metabolic Disease; Inflammation/Immunology
Solubility
– DMSO : 16.67 mg/mL (ultrasonic;warming;heat to 60°C)
Target
– Cytochrome P450
Isoform
– CYP2
Pathway
– Metabolic Enzyme/Protease
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
